Advertisement
Screener

Scilex Holding Company (SCLX) Return on Tangible Equity

2.8 / 5 stars · 68/120 Roast Me

Scilex Holding Co Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Scilex Holding Co return tang equity for the quarter ending 2026-06-30 was 121.75%, a 341.89% increase year-over-year.
  • Scilex Holding Co return tang equity for the quarter ending 2026-03-31 was 120.24%, a 313.80% increase year-over-year.
  • Scilex Holding Co return tang equity for the quarter ending 2025-12-31 was 131.56%, a 331.10% increase year-over-year.
  • Scilex Holding Co return tang equity for the quarter ending 2025-09-30 was 149.54%, a 340.12% increase year-over-year.
  • Scilex Holding Co return tang equity for fiscal 2025 was 131.56%, a 331.10% increase from fiscal 2024.
  • Scilex Holding Co return tang equity for fiscal 2024 was 30.52%, a 40.50% decline from fiscal 2023.
  • Scilex Holding Co return tang equity for fiscal 2023 was 51.29%, a 60.85% decline from fiscal 2022.
  • Scilex Holding Co return tang equity for fiscal 2022 was 131.02%, a 309.18% increase from fiscal 2021.
Available history
2020-12-31 to 2026-06-30
Data captured

Historical Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-06-30121.75%-$464.56M-$381.58M
2026-03-31120.24%-$393.62M-$327.36M
2025-12-31131.56%-$374.05M-$284.32M
2025-09-30149.54%-$334.41M-$223.62M
2025-06-3027.55%-$80.98M-$293.91M
2025-03-3129.06%-$74.51M-$256.42M
2024-12-3130.52%-$72.81M-$238.58M
2024-09-3033.98%-$87.75M-$258.25M
2024-06-3045.27%-$118.89M-$262.63M
2024-03-3145.22%-$107.96M-$238.73M
2023-12-3151.29%-$114.33M-$222.9M
2023-09-3051.86%-$110.82M-$213.66M
2023-06-30129.28%-$53.79M-$41.6M
2023-03-31107.16%-$44.97M-$41.97M
2022-12-31131.02%-$23.36M-$17.83M
2022-09-3033.21%-$93.55M-$281.68M
2022-06-3038.27%-$116.5M-$304.38M
2022-03-3134.84%-$98.9M-$283.85M
2021-12-3132.02%-$88.42M-$276.16M

Annual Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2025-12-31131.56%-$374.05M-$284.32M
2024-12-3130.52%-$72.81M-$238.58M
2023-12-3151.29%-$114.33M-$222.9M
2022-12-31131.02%-$23.36M-$17.83M
2021-12-3132.02%-$88.42M-$276.16M
2020-12-3133.54%-$47.52M-$141.68M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Metagenomi Therapeutics, Inc. (MGX)United States$0.044B-0.48
LeonaBio, Inc. (LONA)United States$0.047B-0.61
Instil Bio, Inc. (TIL)United States$0.048B-1.73
Tevogen Inc. (TVGN)United States$0.049B
aTYR PHARMA INC (ATYR)United States$0.033B-0.98
Quince Therapeutics, Inc. (QNCX)United States$0.031B
CEL SCI CORP (CVM)United States$0.030B-0.81
Inmune Bio, Inc. (INMB)United States$0.056B-2.48
ImageneBio, Inc. (IMA)United States$0.056B-1.31
BioAtla, Inc. (BCAB)United States$0.058B-0.21